Journal
OPHTHALMIC SURGERY LASERS & IMAGING RETINA
Volume 48, Issue 4, Pages 291-+Publisher
SLACK INC
DOI: 10.3928/23258160-20170329-03
Keywords
-
Categories
Funding
- Allergan plc, Dublin
- Accucela
- Alcon
- Alimera
- Allergan
- Bayer
- Genentech
- GSK
- Iconic
- Novartis
- Ophthotech
- Regeneron
- Santen
- Alimera Sciences
- Opthotech
- Allegro
- Apellis
- J-Cyte
- Neurotech
- Ohr
- ThromboGenics
- Acucela
- Aerpio
- Ampio
- Roche
- Allergan plc
Ask authors/readers for more resources
BACKGROUND AND OBJECTIVE: Guidance on the use of corticosteroids in the treatment of diabetic macular edema (DME) is lacking. This study aimed to develop a clinically recommended treatment paradigm for DME with emphasis on the role of corticosteroids. PATIENTS AND METHODS: An expert panel of nine retinal specialists in the United States developed consensus recommendations for DME treatment through a modified Delphi process. RESULTS: The panelists typically use intravitreal injections of vascular endothelial growth factor (VEGF) antagonists as first-line treatment of DME and switch patients with an inadequate response to anti-VEGF therapy (failure of best-corrected visual acuity to improve to 20/40 or better because of edema after three to six monthly injections, or a less-than-50% reduction in excess macular thickness after three to four monthly injections) to intravitreal corticosteroid treatment. CONCLUSION: Intravitreal corticosteroids have a potentially useful role in the treatment of patients with DME who have an inadequate response to intravitreal antiVEGF therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available